meta-Chlorophenylpiperazine
Site K i ( nM ) Species
SERT 202-432 Human
NET 1,940-4,360 Human
DAT ND ND
5-HT 1A 44-400 Human
5-HT 1B 89-501 Human
5-HT 1D 210-1,300 Human
5-HT 1E ND ND
5-HT 1F ND ND
5-HT 2A 32-398 Human
5-HT 2B 3.2-63 Human
5-HT 2C 3.4-251 Human
5-HT 3 427 Human
5-HT 4 ND ND
5-HT 5A 1,354 Human
5-HT 6 1,748 Human
5-HT 7 163 Human
α 1 97-2,900 Human
α 1A 1,386 Human
α 1B 915 Human
α 1D ND ND
Pharmacology -- Pharmacodynamics
meta -Chlorophenylpiperazine ( mCPP ) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. It has been detected in pills touted as legal alternatives to illicit stimulants in New Zealand and pills sold as ecstasy in Europe and the United States . Despite its advertisement as a recreational substance , mCPP is actually generally considered to be an unpleasant experience and is not desired by drug users. It lacks any reinforcing or hallucinogenic effects, produces dysphoric , depressive , and anxiogenic effects in rodents and humans, and can induce panic attacks in individuals susceptible to them. It also worsens obsessive-compulsive symptoms in people with the disorder. mCPP is known to induce headaches in humans and has been used for testing potential antimigraine medications. It has potent anorectic effects and has encouraged the development of selective 5-HT 2C receptor agonists for the treatment of obesity as well.